The first study aimed at the efficacy of PD-1 inhibitors was published by Hamanishi et al. and aimed at evaluating the role of nivolumab (a fully humanized monoclonal antibody against the PD-1 receptor) in ovarian cancer that is resistant to treatment with platinum agents, as other previously suggested [20,86,87]. The gene discussed is PDCD1; the disease is ovarian cancer.